BioAlliance Pharma Signs a Collaborative Agreement With One of the Worldwide Leaders in Vaccines for a Vaccine Application of its Patented Lauriad® Mucoadhesive Technology

  • Email
  • Print

Paris, February 28, 2013 - BioAlliance Pharma SA (Euronext Paris - BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces a collaboration agreement with one of the world leading vaccine companies to develop a vaccine application of its Lauriad® mucoadhesive technology. The terms of this agreement are not disclosed at this time.

This research program aims at establishing the feasibility of using Lauriad® technology for vaccination, leading to an efficient needle-free administration based on the application to the gum of this mucoadhesive tablet containing a vaccine antigen. Moreover, this would also avoid the constraints related to manufacturing sterile injectable forms.

This project is carried out within the Fluriad™ consortium set in March 2011, co-labeled by both "Clusters of excellence" Medicen Paris Region and Atlanpôle Biotherapies and financed up to €2 million by the "Fond Unique Interministériel" (a French program supporting collaborative research projects).

"This collaboration with one of the world leading vaccine companies shows the potential interest of our innovative Lauriad® system for a needle-free vaccination. This is also a major step taken to increase the value of our proprietary Lauriad® technology, already validated through three major products of our portfolio: Loramyc® and Sitavig®, already registered, and Validive®, in phase II clinical development", stated Judith Greciet, CEO of BioAlliance Pharma. "A first successful feasibility would open the way to promising new opportunities in vaccine field with significant market potential worldwide".

About BioAlliance Pharma

Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products, BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.

Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and the USA.

BioAlliance Pharma has developed an advanced product portfolio:

Specialty products
Loramyc®/Oravig® (oropharyngeal candidiasis in immunocompromised patients): Registered in 28 countries (EU, US, Korea)
Sitavir®/Sitavig® (Acyclovir LauriadTM) (labialis herpes): Registered in 8 European countries, registration status in the US
Fentanyl LauriadTM (chronic cancer pain): Positive preliminary Phase I results

Orphan Oncology products
Livatag® (Doxorubicin Transdrug™) (primary liver cancer): Phase III on going
Validive® (Clonidine LauriadTM) (mucositis): Phase II on going
AMEP® (invasive melanoma): Phase I on going
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com

Contact:

BioAlliance Pharma SA
Judith Greciet, CEO
Tel +33 1 45 58 76 00
judith.greciet@bioalliancepharma.com

Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71
nicolas.fellmann@bioalliancepharma.com

ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59
caroline@alizerp.com

Christian Berg
Tel.: +33 1 42 68 86 41
christian@alizerp.com

  • <<
  • >>